IL156828A0 - Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes - Google Patents

Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes

Info

Publication number: IL156828A0
Authority: IL; Israel
Prior art keywords: receptor ligand; gastrin; subjects; composition; therapy methods
Prior art date: 2001-01-12

Application number

IL15682802A

Other languages

English (en)

Original Assignee

Waratah Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-12

Filing date

2002-01-11

Publication date

2004-02-08

2002-01-11 Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc

2004-02-08 Publication of IL156828A0 publication Critical patent/IL156828A0/xx

Links

239000003446 ligand Substances 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 3
230000002035 prolonged effect Effects 0.000 title abstract 3
108010089448 Cholecystokinin B Receptor Proteins 0.000 title abstract 2
102000004859 Cholecystokinin Receptors Human genes 0.000 title abstract 2
108090001085 Cholecystokinin Receptors Proteins 0.000 title abstract 2
102000001301 EGF receptor Human genes 0.000 title abstract 2
108060006698 EGF receptor Proteins 0.000 title abstract 2
102000052874 Gastrin receptors Human genes 0.000 title abstract 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
230000009707 neogenesis Effects 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
239000008103 glucose Substances 0.000 abstract 2
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
210000004153 islets of langerhan Anatomy 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Zoology (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL15682802A 2001-01-12 2002-01-11 Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes IL156828A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26163801P	2001-01-12	2001-01-12
PCT/US2002/000685 WO2002055152A2 (fr)	2001-01-12	2002-01-11	Efficacite prolongee de methodes de soins de neogenese d'ilot avec une composition de ligand de recepteur de gastrine/cck et de ligand de recepteur d'egf chez des sujets a diabetes preexistants

Publications (1)

Publication Number	Publication Date
IL156828A0 true IL156828A0 (en)	2004-02-08

Family

ID=22994183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15682802A IL156828A0 (en)	2001-01-12	2002-01-11	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes

Country Status (13)

Country	Link
US (2)	US6992060B2 (fr)
EP (1)	EP1351742B1 (fr)
JP (1)	JP2004520345A (fr)
KR (1)	KR20040064605A (fr)
CN (1)	CN1486204A (fr)
AT (1)	ATE411077T1 (fr)
AU (1)	AU2002243501B2 (fr)
CA (1)	CA2434330A1 (fr)
DE (1)	DE60229352D1 (fr)
ES (1)	ES2315350T3 (fr)
IL (1)	IL156828A0 (fr)
WO (1)	WO2002055152A2 (fr)
ZA (1)	ZA200305347B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en) *	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
US20060014684A1 (en) *	2000-03-03	2006-01-19	University Technologies International Inc.	Novel uses of EGF
CN1486204A (zh) *	2001-01-12	2004-03-31	��˹ҩƷ��˾	用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
AR036400A1 (es)	2001-08-30	2004-09-08	Stem Cell Therapeutics Inc	Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) *	2001-09-14	2012-02-15	Stem Cell Therapeutics Inc	Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) *	2001-09-18	2003-03-20	Stem Cell Therapeutics Inc.	Effect of growth hormone and IGF-1 on neural stem cells
US7037504B2 (en) *	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
CA2464609A1 (fr) *	2001-10-26	2003-05-01	University Technologies International, Inc.	Utilisation de l'egf pour inhiber les infections pathogenes du tractus urogenital
CN100448483C (zh) *	2002-05-24	2009-01-07	瓦拉塔药品公司	糖尿病的治疗
IL165242A0 (en) *	2002-05-24	2005-12-18	Waratah Pharmaceuticals Inc	Treatment for diabetes
EP1837031B1 (fr) *	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methodes et compositions pour le traitement du diabete
DE60329724D1 (de) *	2002-06-07	2009-11-26	Waratah Pharmaceuticals Inc	Methoden und Kompositionen um Diabetes zu behandeln
CA2492442A1 (fr) *	2002-07-31	2004-02-05	Stem Cell Therapeutics Inc.	Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap)
US20040229810A1 (en) *	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
AU2003283004A1 (en)	2002-10-22	2004-05-13	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
AU2003275853A1 (en) *	2002-10-24	2004-05-13	Mcgill University	Use of ingap for reversing diabetes
CN1829528A (zh) *	2003-05-27	2006-09-06	瓦拉塔药品公司	包含胃泌素化合物的组合物及其在糖尿病中的应用
US20080039379A1 (en) *	2003-05-27	2008-02-14	Waratah Pharmaceuticals, Inc.	Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US20070111932A1 (en) *	2003-07-31	2007-05-17	Stem Cell Therapeutics Inc.	Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005072045A2 (fr) *	2004-01-30	2005-08-11	Waratah Pharmaceuticals, Inc.	Utilisation d'un agoniste de glp-1 associe a des composes gastriniques
CA2556266A1 (fr)	2004-02-13	2005-08-25	Stem Cell Therapeutics Corp.	Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese
EP1765873A4 (fr) *	2004-07-01	2009-07-01	Waratah Pharmaceuticals Inc	Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete
CA2582567A1 (fr) *	2004-10-07	2006-04-13	Stem Cell Therapeutics Corp.	Stimulation de la proliferation de cellules souches pluripotentes par administration de composes associes a la gestation
WO2007036033A1 (fr)	2005-09-27	2007-04-05	Stem Cell Therapeutics Corp.	Regulation par la prolactine de la proliferation des cellules precurseurs d'oligodendrocytes
CN101365476A (zh) *	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
NZ569235A (en) *	2005-12-15	2011-12-22	Nestec Sa	Compositions and methods for preserving brain function using medium chain triglycerides
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
WO2007106987A1 (fr) *	2006-03-17	2007-09-27	Stem Cell Therapeutics Corp.	Régimes de dosage continu pour agents de prolifération des cellules souches nerveuses et agents de différentiation desdites cellules
CN101489578A (zh) *	2006-07-14	2009-07-22	浦项工科大学校产学协力团	表皮生长因子增加胰岛素分泌并降低血糖
WO2008106775A1 (fr) *	2007-03-02	2008-09-12	Waratah Pharmaceuticals Inc.	Traitement d'association du diabète à l'aide d'un ligand du récepteur de l'egf et d'un composé de gastrine
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CN102083451A (zh)	2008-06-12	2011-06-01	赛恩泰新公司	癌症的抑制
GB0820970D0 (en)	2008-11-17	2008-12-24	Syntaxin Ltd	Suppression of cancer
EP2560675A1 (fr)	2010-04-20	2013-02-27	Novo Nordisk A/S	Dérivés de gastrine à action prolongée
KR102027750B1 (ko) *	2018-05-03	2019-10-02	연세대학교 산학협력단	당 배출용 조성물
WO2021002645A1 (fr) *	2019-07-01	2021-01-07	연세대학교 산학협력단	Composition permettant l'excrétion du sucre comportant un hydrogel et un ligand de l'egfr en tant que principes actifs
KR102109385B1 (ko) *	2019-08-21	2020-05-12	연세대학교 산학협력단	당 배출용 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE38892B1 (en)	1973-03-28	1978-06-21	Ici Ltd	Pharmaceutical compositions
JPS6028994A (ja) *	1983-07-08	1985-02-14	Wakunaga Seiyaku Kk	〔２１―ロイシン〕ヒトウロガストロン
GB8409961D0 (en)	1984-04-17	1984-05-31	Searle & Co	Pharmaceutical compositions
US4686283A (en)	1985-04-16	1987-08-11	Syntex (U.S.A.) Inc.	Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
US5102789A (en)	1989-03-15	1992-04-07	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of epideramal growth factor in pichia pastoris yeast cells
US5158935A (en)	1989-05-12	1992-10-27	Chiron Corporation	Human epidermal growth factor having substitution at position 11
IE68593B1 (en)	1989-12-06	1996-06-26	Sanofi Sa	Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5434135A (en)	1990-08-02	1995-07-18	Indu Parikh	Growth factor compositions, preparation and use
WO1993003757A1 (fr)	1991-08-16	1993-03-04	Chiron Corporation	Muteines du facteur de croissance epidermique (fce) presentant une meilleure liaison a un ph faible
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
US5885956A (en) *	1992-12-14	1999-03-23	Research Triangle Pharmaceuticals	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
EP1132091A1 (fr) *	1994-01-24	2001-09-12	The General Hospital Corporation	Traitement du diabète
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en)	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
EP1131350A4 (fr)	1998-11-19	2005-05-04	Millennium Pharm Inc	Acides nucleiques et polypeptides et utilisations correspondantes
WO2000047720A2 (fr)	1999-02-10	2000-08-17	Curis, Inc.	Cellules progenitrices de pancreas et procedes et utilisations associees
US6610535B1 (en)	2000-02-10	2003-08-26	Es Cell International Pte Ltd.	Progenitor cells and methods and uses related thereto
CN1486204A (zh)	2001-01-12	2004-03-31	��˹ҩƷ��˾	用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
CA2442177A1 (fr)	2001-03-29	2002-10-10	Ixion Biotechnology, Inc.	Procede de transdifferentiation de cellules souches non pancreatiques dans la voie de differentiation du pancreas
US7037504B2 (en)	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en)	2002-05-24	2005-12-18	Waratah Pharmaceuticals Inc	Treatment for diabetes
DE60329724D1 (de)	2002-06-07	2009-11-26	Waratah Pharmaceuticals Inc	Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (fr)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methodes et compositions pour le traitement du diabete
AU2003283004A1 (en)	2002-10-22	2004-05-13	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
US20040229810A1 (en)	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
AU2003228097A1 (en)	2003-04-28	2004-11-23	Pirelli Pneumatici S.P.A.	Pneumatic tire provided with a multi-layered tread and process for its manufacture
CN1829528A (zh)	2003-05-27	2006-09-06	瓦拉塔药品公司	包含胃泌素化合物的组合物及其在糖尿病中的应用
WO2005072045A2 (fr)	2004-01-30	2005-08-11	Waratah Pharmaceuticals, Inc.	Utilisation d'un agoniste de glp-1 associe a des composes gastriniques
EP1765873A4 (fr)	2004-07-01	2009-07-01	Waratah Pharmaceuticals Inc	Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete
CN101365476A (zh)	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
EP1971363A1 (fr)	2005-12-02	2008-09-24	Waratah Pharmaceuticals, Inc.	Polythérapies avec des agonistes de la gastrine pour le diabète et des maladies apparentées
WO2007095737A1 (fr)	2006-02-21	2007-08-30	Waratah Pharmaceuticals Inc.	Polythérapie pour le traitement du diabète, comprenant un agoniste d'exendine et un composé de gastrine

2002
- 2002-01-11 CN CNA028036824A patent/CN1486204A/zh active Pending
- 2002-01-11 AU AU2002243501A patent/AU2002243501B2/en not_active Ceased
- 2002-01-11 ES ES02708990T patent/ES2315350T3/es not_active Expired - Lifetime
- 2002-01-11 IL IL15682802A patent/IL156828A0/xx unknown
- 2002-01-11 CA CA002434330A patent/CA2434330A1/fr not_active Abandoned
- 2002-01-11 DE DE60229352T patent/DE60229352D1/de not_active Expired - Fee Related
- 2002-01-11 JP JP2002555881A patent/JP2004520345A/ja active Pending
- 2002-01-11 WO PCT/US2002/000685 patent/WO2002055152A2/fr not_active Ceased
- 2002-01-11 AT AT02708990T patent/ATE411077T1/de not_active IP Right Cessation
- 2002-01-11 EP EP02708990A patent/EP1351742B1/fr not_active Expired - Lifetime
- 2002-01-11 US US10/044,048 patent/US6992060B2/en not_active Expired - Fee Related
- 2002-01-11 KR KR10-2003-7009347A patent/KR20040064605A/ko not_active Ceased
2003
- 2003-07-10 ZA ZA200305347A patent/ZA200305347B/en unknown
2005
- 2005-11-14 US US11/273,615 patent/US7476388B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2002055152A3 (fr)	2003-04-10
JP2004520345A (ja)	2004-07-08
EP1351742B1 (fr)	2008-10-15
US20020098178A1 (en)	2002-07-25
US20060234932A1 (en)	2006-10-19
US7476388B2 (en)	2009-01-13
CA2434330A1 (fr)	2002-07-18
DE60229352D1 (de)	2008-11-27
KR20040064605A (ko)	2004-07-19
EP1351742A2 (fr)	2003-10-15
AU2002243501B2 (en)	2007-11-22
CN1486204A (zh)	2004-03-31
ATE411077T1 (de)	2008-10-15
ES2315350T3 (es)	2009-04-01
WO2002055152A8 (fr)	2002-11-14
US6992060B2 (en)	2006-01-31
WO2002055152A2 (fr)	2002-07-18
WO2002055152A9 (fr)	2003-01-23
ZA200305347B (en)	2004-10-11

Publication	Publication Date	Title
IL156828A0 (en)	2004-02-08	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
IL165285A0 (en)	2005-12-18	Compositions and methods for treating diabetes
WO2004037195A3 (fr)	2005-06-16	Traitement du diabete
LT2002063A (en)	2003-06-25	Low-dose metformin and gliburide combinations for treating diabetes
WO2004004658A3 (fr)	2005-08-04	Procedes et compositions ayant trait a des composes d'isoleucine boroproline
EP0997151A3 (fr)	2000-09-20	Méthode d'administration de peptides à activité insulinotropique
MY124695A (en)	2006-06-30	Novel composition and use.
NO20003051L (no)	2000-06-14	Metode for administrering av AspB28-humant insulin
WO2002053106A3 (fr)	2002-12-19	Composition auto-antigene
SG148850A1 (en)	2009-01-29	Methods of treating vascular disease
WO2001085204A3 (fr)	2002-08-22	Procede et composition therapeutiques faisant appel a un complexe antigene-anticorps et a sa presentation par les cellules dendritiques
WO2004043341A3 (fr)	2004-07-15	Traitement pour choc hémorragique
WO2003101919A3 (fr)	2004-07-22	Ligands macrocycliques pendants de type scorpionates, complexes et compositions contenant ces derniers, et leurs procedes d'utilisation
ZA200110408B (en)	2003-03-19	Methods for treating diabetes.
PL338126A1 (en)	2000-09-25	Treatment of diabetes by means of derivatives of thiazolydinone, of insulin secretion stimulating agent and of biguanidinic derivative
SI0988302T1 (en)	2003-08-31	Benzonaphthyridines
NO20051390L (no)	2005-05-30	Fremgangsmate for behandling av pasienter med massivt blodtap
PT1292315E (pt)	2008-10-16	Utilização de sulodexide para o tratamento da neuropatia diabética
WO1997033620A3 (fr)	1998-02-05	Compose pour traiter des tumeurs
WO2003003971A3 (fr)	2003-12-04	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
WO2003032804A3 (fr)	2003-11-06	Methode permettant d'inverser ou d'empecher la senescence vasculaire prematuree
HUP0002668A2 (hu)	2000-12-28	Diabetes kezelésére dioxo-tiazolidinnel és metforminnal
林凤茹 et al.	1994	FUNCTIONAL STATUS OF PANCREATIC ISLET IN ACUTE LEUKEMIA
AP2000001787A0 (en)	2000-06-30	Use of thiazolidinediones for the treatment of hyperglycaemia.
Brown et al.	2004	Blessed voices.